Advertisement

Diagnosis and Management of Hepatocellular Carcinoma

  • Neal M. Mineyev
  • Karla M. Chaffee
  • Joyce Wong
Chapter

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. This entity typically presents in middle-aged males and is related to the presence of HBV and HCV infection. Patients will often present with weight loss, lethargy, and right upper quadrant pain which prompt workup with routine laboratory studies including a liver function panel, as well as an ultrasound or dedicated liver imaging with a computed tomography (CT) or magnetic resonance imaging (MRI). Once HCC is identified, staging of the disease and workup of liver function is essential to determining the appropriate course of action. Extrahepatic metastasis excludes patients from resection. If not metastatic, tumor burden as well as the patient’s Child-Pugh classification is imperative to determine resectability. Many locoregional therapies exist (radiofrequency ablation (RFA), transarterial chemoembolization (TACE), yttrium-90) for complex patients who may not be eligible for resection or transplantation. Finally, patients with unresectable disease due to underlying severe liver dysfunction are treated with orthotopic liver transplantation if they are within the established Milan criteria.

Keywords

Hepatocellular carcinoma Extrahepatic metastasis Child-Pugh classification Liver resection Liver transplant 

References

  1. 1.
    Townsend CR, Beauchamp MB, Evers M, Mattox K. Sabiston textbook of surgery. 20th ed. Elsevier: Philadelphia, PA. 2016. p. 1458–63.Google Scholar
  2. 2.
    Xavier A, et al. Usefulness of staging systems and prognostic scores for HCC treatments. World J Hepatology. 2016;8(17):703–15.CrossRefGoogle Scholar
  3. 3.
    National Comprehensive Cancer Network, HCC; v.1.2016.Google Scholar
  4. 4.
    Bruix J, et al. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519.CrossRefGoogle Scholar
  5. 5.
    Bruix J, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Neal M. Mineyev
    • 1
  • Karla M. Chaffee
    • 1
  • Joyce Wong
    • 1
  1. 1.Department of General SurgeryLenox Hill HospitalNew YorkUSA

Personalised recommendations